UroGen Pharma Ltd.

Item5. Other Information.

Rule10b5*-1 Trading Arrangement*

During thethree months ended* June 30, 2026,none of our directors or officers adopted, modified or terminated a “Rule10b5*-1 trading arrangement” or “non-Rule10b5-1 trading arrangement,” as each term is defined in Item408 of Regulation S-K.

Supply Agreement

On* April 22, 2026,we entered into a supply agreement (“Supply Agreement”) with TAPI NL B.V. ("TAPI"), effective as of January 1, 2026,*pursuant to which, on a non-exclusive worldwide basis, TAPI agreed to supply, and we agreed to purchase, specified percentages of our commercial requirements for mitomycin for the manufacture, development, and commercialization of certain of our products.

Under the Supply Agreement, mitomycin pricing is fixed, subject to certain permitted adjustments by TAPI, and we* may,under specified circumstances involving TAPI's failure to timely confirm or deliver purchase orders or repeated quality or delivery failures, source a qualified alternative mitomycin material from athird*-party supplier for the affected shortfall quantities, subject to certain limitations set forth in the Supply Agreement.

The Supply Agreement has an initial term often years following the date of ourfirst commercial sale of the finished product that uses mitomycin as the active ingredient, subject to automatictwo-year renewals absent12 months' prior written notice of non-renewal. Either party* mayterminate the Supply Agreement in the case of the other party’s insolvency in the event of an uncured material breach of the other party, or in the event a party determines in good faith, supported by an opinion of independent patent counsel, that continued supply or sale of the mitomycin or the finished product would present a significant risk of infringement of athird* party's intellectual property rights and that party ceases the applicable activities. TAPI* mayalso terminate the Supply Agreement upon a specified period of time of longer thanone* year’s prior written notice if TAPI and its affiliates discontinue all manufacturing of mitomycin, provided that at least a specified period of time longer thanone year remains before the Supply Agreement would otherwise expire.

The foregoing description is qualified in its entirety by reference to the Supply Agreement, which is filed as Exhibit10.1 to this Quarterly Report on Form10-Q.

87